.

.

.
"the big unanswered question is concerns over safety in pregnancy," she says. cgrp levels are lower than normal in pregnant women who have.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention... .
.ai-based software may help predict risk of dementia.. advertisement
.
..